Injectafer Low Phosphate & Bone Injuries

Injectafer is an IV iron given for iron deficiency anemia. On Sept. 1, 2026, FDA added a boxed warning, its most prominent, for symptomatic hypophosphatemia, or dangerously low phosphate1. FDA said severe, long-lasting low phosphate can lead to osteomalacia (bone softening) and fractures, and that phosphate is tested in fewer than 20% of Injectafer treatment episodes1. A warning alone does not make a legal claim. An Injectafer lawyer looks at the infusions, the lab results and the bone injury.

What FDA added in 2026

Injectafer (ferric carboxymaltose) was approved in 2013 for iron deficiency anemia in people who cannot tolerate or do not respond to oral iron, and later for some patients with kidney disease or heart failure1. The new boxed warning describes the risk of symptomatic hypophosphatemia and recommends phosphate monitoring for patients at risk and for anyone getting a repeat course within three months1.

FDA said symptoms of low phosphate can include1:

• Muscle weakness or pain
• Fatigue
• Bone and joint pain
• Tremors and confusion
• Seizures and heart rhythm problems

FDA noted that some symptoms can look like iron deficiency anemia itself, so they can be missed1. The label says symptomatic hypophosphatemia has occurred even in people without obvious risk factors2.

How the Injectafer warning developed

Injectafer phosphate warnings

1. 2013

   FDA approves Injectafer1.

2. 2019

   FDA determines that the drug can cause serious symptomatic hypophosphatemia1.

3. February 2020

   A warning about the risk is added to the label1.

4. 2023

   The warning adds phosphate monitoring advice, osteomalacia and fractures, and inflammatory bowel disease as a risk factor1.

5. 2025

   More risk factors are added1.

6. Sept. 1, 2026

   FDA adds a boxed warning after finding that symptomatic cases continued to be reported1.

What the IV iron trials found

Two randomized trials published in JAMA in 2020 compared Injectafer with another IV iron, ferric derisomaltose. Low phosphate (below 2.0 mg/dL) occurred in 75.0% and 73.7% of Injectafer patients, compared with 7.9% and 8.1% on the other iron3. The authors said more research was needed on the clinical importance of the difference3.

FDA reported that consequences in its case reports included hospital stays, weeks to months of phosphate replacement and extended follow-up care1.

The litigation

There is no federal multidistrict litigation for Injectafer on the JPML's Nov. 2, 2026 report4. Cases are brought individually. A label warning, even a boxed one, does not by itself establish a viable claim. What matters is the documented injury, the treatment timeline and what the warning said when you were treated.

Who may have an Injectafer claim

• The dates and number of Injectafer infusions
• Phosphate levels before and after, if tested
• Symptoms and when they started
• Diagnosis of osteomalacia, fractures or hospitalization
• Other causes of low phosphate or bone loss

You do not need every record before contacting us.

Who may be responsible

An investigation may look at the company that made and labeled Injectafer and at what the warning said on your treatment dates. Whether phosphate was monitored may raise separate medical questions.

Filing deadlines for Injectafer lawsuits

Deadlines depend on your state and on when you learned of the injury and its possible cause. Examples:

• Arizona: generally two years for personal injury and wrongful death5.
• California: two years for injury to or death of a person caused by another's wrongful act or neglect6.
• New York: three years for personal injury7, with a separate rule that runs from discovery for injuries caused by the latent effects of exposure to a substance in the body8.
• Texas: two years for personal injury and wrongful death9, and most product liability claims must be brought within 15 years of the product's sale, with an exception for certain latent diseases10.

When the clock starts can depend on when a person knew, or should have known, about the injury and its possible link to the medicine. Rules for children, wrongful death and claims against public hospitals can differ. Ask an Injectafer attorney to check the rules for your state early, before records are lost.

Tell Us Your Story →

Records that help an Injectafer review

Records worth gathering

Infusions

• Infusion center records
• Dates and doses
• Reason for IV iron

Labs and bones

• Phosphate and vitamin D labs
• X-rays, bone scans or DEXA
• Fracture treatment records

Impact

• Hospital records
• Phosphate replacement prescriptions
• Bills and time off work

What happens after you contact CBW Law

How a review works

1. Tell us what happened

   Tell us about your infusions, symptoms and any fractures. You do not need every record first.

2. We match infusions to labs

   We line up your infusion dates with phosphate results and bone findings.

3. We gather records

   With your permission, we request pharmacy, medical and billing records from the places that treated you.

4. We explain what we see

   We tell you what the records show, what questions remain and what options may be open, including deadlines.

A boxed warning does not by itself make a legal claim. An Injectafer claim depends on documented low phosphate and the harm that followed.

Plain English

Medical, Health & Insurance

Terms you may see in an Injectafer case.

Drug terms

Ferric carboxymaltose

The IV iron in Injectafer.

Ferric derisomaltose

A different IV iron used in comparison trials3.

Condition terms

Hypophosphatemia

Low phosphate in the blood1.

Osteomalacia

Softening of the bones1.

Insufficiency fracture

A break in weakened bone under normal stress.

Testing and coverage

Serum phosphate

A blood test of phosphate levels.

DEXA scan

A bone density test.

Questions

Injectafer lawsuit questions

Short answers to the questions people ask first.

Is there an Injectafer lawsuit?

Individual claims can be reviewed. There is no federal MDL for Injectafer on the current JPML report.

When did Injectafer get a boxed warning?

FDA announced it on Sept. 1, 2026. A warning about low phosphate has been in the label since February 2020.

Does the boxed warning mean I have a case?

No. An Injectafer lawyer looks at your lab results, injuries and treatment dates.

I was never tested for phosphate. Can I still ask?

Yes. Symptoms, later labs and bone findings can still be reviewed.

Can low phosphate cause fractures?

FDA says chronic severe low phosphate may lead to bone softening and fractures.

Do other IV irons carry the same risk?

Trials found much lower rates with ferric derisomaltose. An Injectafer attorney focuses on the product you received.

How long do I have to file an Injectafer lawsuit?

It depends on your state and on when you learned of the injury and its possible link to the infusions.

Should I stop iron treatment?

Talk with your doctor. Iron deficiency also needs treatment.

What records matter most?

Infusion records, phosphate labs and any imaging of bone injuries.

What does it cost to contact CBW Law?

Telling us your story costs nothing, and contacting us does not create an attorney-client relationship.

Tell Us Your Story

If Injectafer infusions were followed by severe low phosphate, bone pain or fractures, an Injectafer attorney can review your records.

Tell us what happened. CBW Law will review your information and explain what we see. Submitting information does not establish an attorney-client relationship or guarantee representation.

Tell Us Your Story →Call (800) 476-2416

This page is general information about Injectafer and low phosphate. It is not legal or medical advice and does not create an attorney-client relationship. Do not change any treatment without your doctor. A boxed warning does not by itself establish that the drug caused any person's injury or that a legal claim exists. Laws and deadlines differ by state, and no outcome can be promised.